NO986209L - Ikke-vandige protiske peptidformuleringer - Google Patents

Ikke-vandige protiske peptidformuleringer

Info

Publication number
NO986209L
NO986209L NO986209A NO986209A NO986209L NO 986209 L NO986209 L NO 986209L NO 986209 A NO986209 A NO 986209A NO 986209 A NO986209 A NO 986209A NO 986209 L NO986209 L NO 986209L
Authority
NO
Norway
Prior art keywords
peptide formulations
aqueous protic
protic peptide
aqueous
formulations
Prior art date
Application number
NO986209A
Other languages
English (en)
Other versions
NO986209D0 (no
NO323933B1 (no
Inventor
James B Eckenhoff
Cynthia L Stevenson
Sally Tao
Steven J Prestrelski
Jeremy C Wright
Joe Leonard
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of NO986209L publication Critical patent/NO986209L/no
Publication of NO986209D0 publication Critical patent/NO986209D0/no
Publication of NO323933B1 publication Critical patent/NO323933B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
NO19986209A 1996-07-03 1998-12-30 Stabil ikke-vandig formulering av en peptidforbindelse, fremgangsmate for fremstilling av denne og anvendelse av formuleringen til fremstillig av medikament. NO323933B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2112996P 1996-07-03 1996-07-03
PCT/US1997/010815 WO1998000152A1 (en) 1996-07-03 1997-07-01 Non-aqueous protic peptide formulations

Publications (3)

Publication Number Publication Date
NO986209L true NO986209L (no) 1998-12-30
NO986209D0 NO986209D0 (no) 1998-12-30
NO323933B1 NO323933B1 (no) 2007-07-23

Family

ID=21802501

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19986209A NO323933B1 (no) 1996-07-03 1998-12-30 Stabil ikke-vandig formulering av en peptidforbindelse, fremgangsmate for fremstilling av denne og anvendelse av formuleringen til fremstillig av medikament.

Country Status (27)

Country Link
EP (1) EP0909175B1 (no)
JP (3) JP2001504802A (no)
CN (1) CN1231256C (no)
AR (1) AR008060A1 (no)
AT (1) ATE241997T1 (no)
AU (1) AU737664B2 (no)
BR (1) BR9710130A (no)
CA (1) CA2259403A1 (no)
CO (1) CO4890854A1 (no)
CZ (1) CZ433898A3 (no)
DE (1) DE69722620T2 (no)
DK (1) DK0909175T3 (no)
ES (1) ES2201306T3 (no)
HU (1) HUP9903942A3 (no)
ID (1) ID19165A (no)
IL (1) IL127769A (no)
MY (1) MY121684A (no)
NO (1) NO323933B1 (no)
NZ (1) NZ333580A (no)
PL (1) PL189402B1 (no)
PT (1) PT909175E (no)
RO (1) RO119862B1 (no)
RU (1) RU2203085C2 (no)
SK (1) SK284490B6 (no)
TW (1) TW491703B (no)
WO (1) WO1998000152A1 (no)
ZA (1) ZA975942B (no)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU737664B2 (en) * 1996-07-03 2001-08-30 Alza Corporation Non-aqueous protic peptide formulations
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
US7919109B2 (en) 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
WO2003002136A2 (en) 2001-06-28 2003-01-09 Novo Nordisk A/S Stable formulation of modified glp-1
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
ES2359243T3 (es) * 2003-04-25 2011-05-19 Boston Scientific Scimed, Inc. Formulación de fármaco sólida y dispositivo para el almacenamiento y la administración controlada de la misma.
DK3300721T4 (da) * 2003-11-20 2025-03-03 Novo Nordisk As Propylenglycol-holdige peptidformuleringer hvilke er optimale til fremstilling og til anvendelse i injektionsindretninger
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
KR101106510B1 (ko) 2006-05-30 2012-01-20 인타르시아 세라퓨틱스 인코포레이티드 투피스, 내부채널 삼투압 전달 시스템 유동 조절기
EP2359808B1 (en) 2006-08-09 2013-05-22 Intarcia Therapeutics, Inc Osmotic delivery systems and piston assemblies
AU2013203271B2 (en) * 2007-01-19 2016-05-12 Hananja Ehf Methods and compositions for the delivery of a therapeutic agent
CN101678112B (zh) * 2007-01-19 2016-08-31 哈南亚有限公司 用于递送治疗剂的方法和组合物
US20080275030A1 (en) 2007-01-19 2008-11-06 Sveinbjorn Gizurarson Methods and Compositions for the Delivery of a Therapeutic Agent
WO2008133908A2 (en) 2007-04-23 2008-11-06 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
CA2691531C (en) 2007-06-22 2016-11-01 Board Of Regents,The University Of Texas System Formation of stable submicron peptide or protein particles by thin film freezing
CA2726861C (en) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
CA2730760A1 (en) * 2008-07-16 2010-01-21 Surmodics Pharmaceuticals, Inc. Process for preparing microparticles containing bioactive peptides
PE20110543A1 (es) 2008-08-15 2011-08-04 Ironwood Pharmaceuticals Inc Formulacion solida oral que comprende linaclotida, cation de calcio y leucina
EP2376522A4 (en) 2008-11-16 2013-12-25 Univ Texas LOW VISCOSIS HIGHLY CONCENTRATED SUSPENSIONS
CA2770077A1 (en) 2009-08-06 2011-02-10 Ironwood Pharmaceuticals, Inc. Formulations comprising linaclotide
RU2547990C2 (ru) 2009-09-28 2015-04-10 Интарсия Терапьютикс, Инк. Быстрое достижение и/или прекращение существенной стабильной доставки лекарственного средства
UA108636C2 (xx) 2010-02-17 2015-05-25 Пептид
EP2603232B1 (en) 2010-08-11 2019-09-25 Ironwood Pharmaceuticals, Inc. Stable formulations of linaclotide
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
MX347354B (es) 2011-08-17 2017-04-24 Ironwood Pharmaceuticals Inc Tratamientos para trastornos gastrointestinales.
US20130288968A1 (en) * 2012-04-30 2013-10-31 Sun Pharmaceutical Industries Ltd. Leuprolide injection
WO2014124096A1 (en) * 2013-02-06 2014-08-14 Perosphere Inc. Stable glucagon formulations
EP2823808A1 (en) * 2013-07-09 2015-01-14 Ipsen Pharma S.A.S. Pharmaceutical composition for a sustained release of lanreotide
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
RU2730996C2 (ru) 2015-06-03 2020-08-26 Интарсия Терапьютикс, Инк. Системы установки и извлечения имплантата
KR102574993B1 (ko) 2016-05-16 2023-09-06 인타르시아 세라퓨틱스 인코포레이티드 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
JP7286542B2 (ja) 2017-01-03 2023-06-05 インターシア セラピューティクス，インコーポレイティド Ｇｌｐ－１受容体アゴニストの持続的投与及び薬物の同時投与を含む方法
EP3372224A1 (en) 2017-03-07 2018-09-12 Alrise Biosystems GmbH New controlled drug delivery system using water miscible solvents for production of drug loaded micro- and nanoparticles
KR102665710B1 (ko) 2017-08-24 2024-05-14 노보 노르디스크 에이/에스 Glp-1 조성물 및 그 용도
JP7761567B2 (ja) 2020-02-18 2025-10-28 ノヴォ ノルディスク アー／エス 医薬製剤

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897256A (en) * 1986-11-25 1990-01-30 Abbott Laboratories LHRH analog formulations
DE3886880T2 (de) * 1987-10-15 1994-07-14 Syntex Inc Pulverförmige Zubereitungen zur intranasalen Verabreichung von Polypeptiden.
US4980163A (en) * 1989-03-01 1990-12-25 Public Health Research Institute Of The City Of New York Novel bacteriocin compositions for use as enhanced broad range bactericides and methods of preventing and treating microbial infection
US5158761A (en) * 1989-04-05 1992-10-27 Toko Yakuhin Kogyo Kabushiki Kaisha Spray gel base and spray gel preparation using thereof
IT1237197B (it) * 1989-11-16 1993-05-26 Sclavo Spa Formulazioni farmaceutiche anidre e forme di dosaggio per la somministrazione rettale di calcitonina.
RU2008354C1 (ru) * 1991-03-13 1994-02-28 Данилевич Василий Николаевич Способ хранения препарата протеиназ
ES2107051T3 (es) * 1992-09-21 1997-11-16 Upjohn Co Formulaciones de proteinas de liberacion sostenida.
AU685784B2 (en) * 1993-02-23 1998-01-29 Genentech Inc. Excipient stabilization of polypeptides treated with organic solvents
US5955430A (en) * 1993-09-24 1999-09-21 University Of Southern California Use of angiotensin II fragments and analogs thereof in tissue repair
JP3597233B2 (ja) * 1993-10-21 2004-12-02 久光製薬株式会社 経鼻組成物及びそれを含有する経鼻製剤
AU737664B2 (en) * 1996-07-03 2001-08-30 Alza Corporation Non-aqueous protic peptide formulations

Also Published As

Publication number Publication date
EP0909175B1 (en) 2003-06-04
AR008060A1 (es) 1999-12-09
ATE241997T1 (de) 2003-06-15
DE69722620T2 (de) 2004-04-29
PL189402B1 (pl) 2005-08-31
JP2008195739A (ja) 2008-08-28
CZ433898A3 (cs) 1999-04-14
NZ333580A (en) 2000-06-23
IL127769A (en) 2006-10-31
EP0909175A1 (en) 1999-04-21
RU2203085C2 (ru) 2003-04-27
ZA975942B (en) 1998-04-16
ES2201306T3 (es) 2004-03-16
RO119862B1 (ro) 2005-05-30
MY121684A (en) 2006-02-28
CA2259403A1 (en) 1998-01-08
NO986209D0 (no) 1998-12-30
IL127769A0 (en) 1999-10-28
AU737664B2 (en) 2001-08-30
CN1231256C (zh) 2005-12-14
WO1998000152A1 (en) 1998-01-08
ID19165A (id) 1998-06-28
PL330869A1 (en) 1999-06-07
BR9710130A (pt) 1999-08-10
SK179998A3 (en) 1999-05-07
CO4890854A1 (es) 2000-02-28
DE69722620D1 (de) 2003-07-10
TW491703B (en) 2002-06-21
SK284490B6 (sk) 2005-05-05
DK0909175T3 (da) 2003-09-29
HUP9903942A3 (en) 2000-07-28
CN1224356A (zh) 1999-07-28
JP2001504802A (ja) 2001-04-10
PT909175E (pt) 2003-10-31
NO323933B1 (no) 2007-07-23
HUP9903942A2 (hu) 2000-04-28
JP2010043105A (ja) 2010-02-25
AU3407397A (en) 1998-01-21

Similar Documents

Publication Publication Date Title
NO986209L (no) Ikke-vandige protiske peptidformuleringer
NO986207L (no) Ikke-vandige polare aprotiske peptidformuleringer
NO986208L (no) Vandige peptidformuleringer
NO982519D0 (no) Formet ladning
MA24473A1 (fr) Formulations
DE59702237D1 (de) Abtrennvorrichtung
DE59712446D1 (de) Leistungsschalter
NO985680L (no) Peptidderivater
DE59708688D1 (de) Trennschalter
DE59711825D1 (de) Leistungsschalter
NO983849D0 (no) Peptidderivater
NO962167D0 (no) Deflektoranordning
DK0832553T3 (da) Mejetærsker
DE59710361D1 (de) Weichenendverschluss
NO965214D0 (no) Deflektor
DE69802853D1 (de) Schutzschalter
ATE235511T1 (de) Vielfältig verzweigte peptidkonstruktionen
DE69813938D1 (de) Schaltröhre
DE59703536D1 (de) Grenzwertschalter
KR970052895U (ko) 접지용 단자
NO965617L (no) Skillebryter
DK1017798T3 (da) Lunasinpeptider
NO20000976D0 (no) Peptider
SE9802536D0 (sv) Novel peptides
EE00163U1 (et) Suusad

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees